Phase II trial of recombinant interleukin-1β in patients with metastatic renal cell carcinoma

Interleukin-1 (IL-1) plays a central role in the immune system, partly by stimulating the production of interleukin-2 (IL-2) and other cytokines by lymphocytes. In preclinical studies, recombinant interleukin-1 (rIL-1 beta) has shown antitumor activity. We conducted a phase II trial to evaluate the...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of immunotherapy 1994-10, Vol.16 (3), p.211-215
Hauptverfasser:	REDMAN, B. G, YOUSIF ABUBAKR, TA-HSU CHOU, ESPER, P, FLAHERTY, L. E
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic agents Biological and medical sciences Carcinoma, Renal Cell - blood Carcinoma, Renal Cell - secondary Carcinoma, Renal Cell - therapy Female Humans Immunotherapy Interleukin-1 - adverse effects Interleukin-1 - therapeutic use Interleukin-6 - blood Male Medical sciences Middle Aged Pharmacology. Drug treatments Receptors, Interleukin-2 - analysis Recombinant Proteins - adverse effects Recombinant Proteins - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!